h.yilmaz98/100
Certificate carries peptide content stated separately from purity. Complete against the index minimum data set at first issue. Vial-to-vial mass variation under 2%.
BCH — Bachem Holding (Suzhou) Co., Ltd.
Suzhou, CN · established 2003. The index holds 209 assay reports across 39 batches and 23 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where BCH sells
Bachem Holding (Suzhou) Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit BCH at bachemholding.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Bachem Holding (Suzhou) Co., Ltd.
- Short code in this index
- BCH
- Also known as
- BCH · BCH Biotech · Bachem Holding (Suzhou)
- Domain
- bachemholding.com →
- City
- Suzhou
- Region
- Suzhou
- Country
- CN
- Established
- 2003
- First record in index
- 28 Jan 2024
- Most recent record
- 26 Sep 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
11.5%
n=209
Retail, shipped to the buyer
62.7%
n=209
Direct to the laboratory
20.1%
n=209
Median courier leg, direct despatch
6d
n=42
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 24 | 11.5% |
| Retail purchase, shipped to the buyer | 107 | 51.2% |
| Retail purchase via a third-party forwarder | 24 | 11.5% |
| Supplier despatch direct to the laboratory | 42 | 20.1% |
| Laboratory retained-sample archive | 12 | 5.7% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 209 BCH records the index holds, 24 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 12 of the 23 compounds BCH is represented by here — BPC-157, Tirzepatide, Afamelanotide, Cagrilintide, GHRP-2, MOTS-c and 6 further compounds. Those are the BCH lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for BCH. 24 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is BCH's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it. Where BCH despatched a sample direct to a laboratory, the courier leg ran a median 6 days across 42 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.32%
n=209
Interquartile range
1.11pp
n=209
10th percentile
97.37%
n=209
Pass rate vs index spec
78.9%
n=209
Median recovery vs claim
97.7%
n=129
Median water
5.14%
n=209
Median |mass error|
2.4ppm
n=181
Records carrying a flag
37.3%
n=209
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
1.00pp
n=28
Index median spread
0.67pp
n=28
Lots tested 3+ times
28
n=39
Across the 28 BCH lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 1.00 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=39
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
54%
n=39
Divergences beyond 1 pp
0%
n=39
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.21%
n=155
Supplier-supplied median
98.70%
n=42
Supplier-supplied share of records
20.1%
n=209
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of BCH batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
67/100
n=39
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 59% | 25 points | |
| Peptide content stated | 44% | 20 points | |
| Endotoxin stated | 28% | 15 points | |
| Named impurities rather than a total | 19% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 34 | 97.50 | 98.55 | -1.05 | 97.0 | 88 |
| BPC-157 | Tissue-repair | 32 | 98.72 | 99.16 | -0.44 | 98.0 | 94 |
| Semaglutide | Incretin | 21 | 98.03 | 98.89 | -0.86 | 97.0 | 100 |
| Cagrilintide | Incretin | 19 | 99.05 | 98.69 | +0.36 | 96.5 | 100 |
| CJC-1295 with DAC | Growth-hormone | 16 | 97.87 | 98.95 | -1.08 | 97.5 | 88 |
| MOTS-c | Metabolic | 14 | 98.16 | 99.13 | -0.97 | 98.0 | 79 |
| Gonadorelin | Hypothalamic | 14 | 98.88 | 99.12 | -0.24 | 98.5 | 86 |
| GHRP-2 | Growth-hormone | 9 | 98.77 | 99.28 | -0.52 | 99.0 | 11 |
| VIP | Tissue-repair | 9 | 97.43 | 97.56 | -0.13 | 97.5 | 44 |
| Afamelanotide | Melanocortin-receptor | 7 n=7 | 97.86 | 99.06 | -1.20 | 98.0 | 43 |
| CJC-1295 (no DAC) | Growth-hormone | 5 n=5 | 98.02 | 99.09 | -1.07 | 98.0 | 60 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 4 n=4 | 98.23 | 99.49 | -1.26 | 98.5 | 50 |
| GHRP-6 | Growth-hormone | 4 n=4 | 98.75 | 99.54 | -0.79 | 99.0 | 25 |
| MGF | Growth-hormone | 4 n=4 | 99.22 | 99.29 | -0.08 | 97.5 | 100 |
| AOD-9604 | Metabolic | 3 n=3 | 98.27 | 99.29 | -1.02 | 98.0 | 100 |
| Hexarelin | Growth-hormone | 3 n=3 | 97.97 | 99.59 | -1.62 | 99.0 | 0 |
| Retatrutide | Incretin | 3 n=3 | 97.02 | 98.37 | -1.35 | 96.5 | 100 |
| Ipamorelin | Growth-hormone | 2 n=2 | n<3 | 99.47 | — | 99.0 | 50 |
| L-Glutathione (reduced) | Short | 2 n=2 | n<3 | 99.33 | — | 98.5 | 0 |
| TB-500 | Tissue-repair | 1 n=1 | n<3 | 99.53 | — | 98.5 | 100 |
| Pemvidutide | Incretin | 1 n=1 | n<3 | 98.25 | — | 96.0 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 1 n=1 | n<3 | 99.38 | — | 98.5 | 100 |
| Selank | Neuroactive | 1 n=1 | n<3 | 99.59 | — | 99.0 | 0 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 1 | 7 | 97.86 | 97.57–98.87 | 1 |
| 2024-Q2 | 2 | 16 | 97.92 | 97.37–98.60 | 1 |
| 2024-Q3 | 5 | 27 | 97.63 | 96.37–99.21 | 4 |
| 2024-Q4 | 2 | 16 | 98.27 | 96.98–99.10 | 10 |
| 2025-Q1 | 1 | 5 | 98.02 | 97.41–98.23 | 5 |
| 2025-Q2 | 6 | 24 | 97.78 | 96.81–99.93 | 5 |
| 2025-Q3 | 3 | 5 | 98.91 | 97.44–99.11 | 1 |
| 2025-Q4 | 7 | 53 | 98.89 | 97.60–99.93 | 17 |
| 2026-Q1 | 5 | 19 | 98.70 | 97.90–99.79 | 4 |
| 2026-Q2 | 4 | 13 | 98.72 | 97.09–99.46 | 9 |
| 2026-Q3 | 3 | 24 | 98.15 | 97.42–99.74 | 21 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 100 | 98.35 | +0.00 | 98.35 |
| PeptideMeter | 34 | 98.10 | -0.05 | 98.15 |
| Medutest | 31 | 98.50 | +0.08 | 98.42 |
| VendorInvestigate | 21 | 98.04 | -0.11 | 98.15 |
| Nordanalyt | 13 | 98.27 | +0.02 | 98.25 |
| Kestrel | 10 | 98.38 | +0.24 | 98.14 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
89.0/ 100824 ratings across the index network
c.adeyemi99/100
Cold chain intact. Phase-change pack solid at arrival, day 8. No further comment.
z.chowdhury95/100
Reconstitution of semaglutide 5 mg: clear on contact, no haze, no particulate. Subsequent orders placed with the same supplier.
ju.iyer96/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. PeptideMeter report held on file, figures match published. Further submissions on later lots would improve coverage.
a.vasquez92/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification.
c.batista95/100
Supplementary certificate for a lot released 10 months earlier retrieved from supplier records on request.
se.silva96/100
Labelling printed, lot and date legible on every unit examined. Research use. Not approved for human administration.
a.restrepo97/100
Consistency: 3 lots, purity band under 1.0 points wide. Signature and release date present. Not medical advice.
h.solberg96/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination.
p.chukwu100/100
Dispatch on the quoted day. Material returned 97.2%. No adverse observation.
s.broberg98/100
Residual-solvent screen included unrequested. Independent verification of individual lots still required.
m.cabrera97/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Reorder at 9 months within 0.1 points of the original.
i.danquah95/100
11 orders, 24 months. No substitution, no reformulation, no post-payment unavailability. Vial-to-vial mass variation under 2%. Record covers the lots named. Not generalised.
m.chukwu99/100
Direct-supply material 99.1%. Intermediary vial, same nominal description, 99.0%. Signature and release date present.
m.asante97/100
Lot BCH-26-897 submitted to Janoshik. Declared 98.2%, reported 98.3%. Delta inside method repeatability. Submitted to the index in full.
t.stanescu96/100
Retention time assigned to the principal peak, printed. No further comment.
s.lindholm99/100
Fill uniformity: 9 units weighed against declared fill, all within 2%.
d.rahimi98/100
Peptide content reported separately from chromatographic purity across all 12 certificates held. Further submissions on later lots would improve coverage.
b.coelho96/100
Water content by Karl Fischer, method named. n=1, declared as n=1.
r.rasmussen100/100
Labels square and legible on every unit, lot code matching the paperwork. Figures as reported by the named service. Not reproduced by the index.
k.bakken100/100
Labels square and legible on every unit, lot code matching the paperwork throughout the consignment.
g.correia95/100
Declared figure not adjusted upward between certificate and commercial documentation. Janoshik report held on file, figures match published.
e.trevino100/100
Twelve vials examined on receipt, no glass defects and no shifted cakes. Identifier matches across vial, certificate and commercial documentation. Evidence base adequate for a rating on this criterion.
e.wikstrom97/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Reorder at 8 months within 0.1 points of the original. No adverse observation.
l.erdogan95/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Gradient and column chemistry stated. Figures as reported by the named service. Not reproduced by the index.
g.vasquez96/100
Packing: the invoice sealed in its own sleeve rather than loose against the vials. Signature and release date present.
Block 12
Most recent records
Block 13
Contributor annotations on BCH records 344
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on BCH material are below, each linked to the record it sits on.
The more useful question than the rounding is whether the certificate states the method. Where it does, a rounded figure is comparable; where it does not, an unrounded one still is not.
The measured value on this record carries two decimals because the integration produced two. That is the honest form of the same quantity, and it is available from the supplier as well.
Any covalent dimer would appear at roughly twice the parent mass, and on a cysteine-containing sequence at twice the parent minus two hydrogens. The envelope on this record shows no series at either offset.
Instrument class is on the record, which is what allows -3.4 ppm to be read at its proper weight. The index distinguishes "confirmed" from "consistent with" precisely on this field.
Mass at +2.1 ppm establishes identity but not content. Absolute content needs a standard or an orthogonal quantitative method, and neither is a mass spectrometer.
Spectral homogeneity across the main peak would complete this record. Mass confirms what eluted; the spectrum confirms that only one thing did.
One retail vial is one draw from a fill. Two or three from the same lot would separate fill variation from lot quality, and that is the cheapest useful experiment in this whole field.
Rule AX-R04 carries the lowest severity in the rule set for a reason. It is a finding about how a number was written down.
Every annotation the index holds on BCH material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what BCH itself publishes, open bachemholding.com → alongside.
Block 14
Where to buy BCH
Bachem Holding (Suzhou) Co., Ltd. sells direct from bachemholding.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the BCH store at bachemholding.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.